Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

UNICEF Highlights Child Survival On The Day Of The African Child
Several African countries have made impressive gains in child survival in recent years but much more needs to be done, UNICEF said today in marking the International Day of the African Child. This year"s theme is "Africa Fit for Children: A Call for Accelerated Action Towards Child Survival".
generic viagra online
Children's Hospitals And Clinics Of Minnesota Receive Level III Trauma Designation
The Minnesota Department of Health recently designated Children"s Hospitals and Clinics of Minnesota"s two hospital locations as Level III Trauma Hospitals. Children"s of Minnesota has the sixth busiest pediatric emergency department in the nation with over 84,000 visits per year, and already treats around 450 trauma cases each year. Children"s voluntarily participated in the intense designation process, which included an external review of the hospitals" res and capabilities to care for young trauma patients. Children"s met the required standards of commitment, clinical and equipment res, and staff training.
News of the day
Progress Seen In Some African HIV/AIDS Prevention, Treatment Programs, U.N. Special Envoy Says At World Economic Forum On Africa
Several African countries have successfully scaled up their HIV/AIDS prevention and treatment programs, U.N. Special Envoy for HIV and AIDS in Africa Elizabeth Mataka said during a media briefing at the World Economic Forum on Africa being held in Cape Town, South Africa, the ZANIS/Lusaka Times reports. Zambia and Botswana were among some of the countries that have made significant progress in southern Africa, according to Mataka.
Medical Devices

Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target. The low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system. "We are delighted to strengthen our product portfolio by advancing another novel Nanobody®, discovered using our proprietary Nanobody® platform, into preclinical development. It is well positioned to translate into a superior treatment for rheumatoid arthritis and other autoimmune diseases. There are already three Nanobodies® in clinical development, with our lead programme, ALX-0081, a novel anti-thrombotic, on track to start Phase II in the next few months", commented Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx. About ALX-0061 (IL6R) ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R). It has the potential to differentiate through its high potency, high stability and low molecule weight of only 26kD which should translate into superior tissue penetration, attractive PK/PD and superior safety and efficacy profile compared with a benchmark monoclonal antibody. The involvement of the IL6 pathway in a variety of diseases indicates that multiple indications can be pursued with large market potential including rheumatoid arthritis (RA), Crohn"s disease, Castleman"s disease, multiple myeloma and systemic lupus erythematosus (SLE). College Hill Life Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009